Evgen Pharma Share Discussion Threads

[moneymunch] 26/5/2020 06:38

Lol...another poignant tune for the times by Bob and my fence is still in the planning stage, but will definitley be going UP this week along with EVG's share price ...Gl ;-)

[toffeeman] 25/5/2020 22:00

What does Mr Zimmerman have to do with the price of fish?

How's your fence?

[moneymunch] 25/5/2020 09:28

Long standing collaboration between AstraZeneca and University of Manchester as well as a long standing collobaration with Evgen, the blockbuster cancer drugs Tamoxifen and Fulvestrant are both marketed by AstraZeneca and the recent phase 11 trials for SFX-01 confirm that both drugs in combination improves clinical outcomes, which would suggest that AstraZeneca could be a potential partner for SFX-01's development.

AstraZeneca also have two drugs in patient trials for Covid-19, via the the Govt's Accord platform, and so more than conceivable that they could be the potential funding source for SFX-01's proposed Covid-19 patient trials, given the fact that through the University of Manchester's collaboration, they must be very much aware of the attributes and potential of SFX-01....Gla Holders....Fingers crossed for stellar news soon. ;-)

"SFX-01 reduced MFE of both ER+ primary and metastatic patient samples. Both tamoxifen and fulvestrant increased MFE and ALDH activity of PDX tumors, which was reversed by combination with SFX-01."

7/5/20

Two AstraZeneca molecules to be explored as Covid-19 treatments under government’s ACCORD platform

Published:07 May 2020


The AstraZeneca molecules being explored in this first wave are a Bruton’s tyrosine kinase (BTK) inhibitor previously approved for a different indication, and a phase II drug candidate targeting interleukin 33 (IL-33).

Evidence shows how a hyper-activated immune response in Covid-19 patients can result in pneumonia, respiratory failure and death.






University of Manchester

“Through extensive close collaborative clinical and laboratory work with colleagues at locally based AstraZeneca, Manchester researchers have successfully improved treatments over the years. Today, more women presenting with early breast cancer are cured, remission in advanced disease lasts longer and survival is prolonged."





6/2/20

University of Manchester collaboration discovery

Gene signature identified which may determine response to SFX-01 in ER+ breast cancer treatment

Evgen closer to predicting which patients are most likely to benefit from breast cancer drug

Steve Franklin, CEO of Evgen Pharma, said: "This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with potential partners. The University of Manchester have been tremendous collaborators and we would like to thank them for their continued commitment and enthusiasm.

[moneymunch] 25/5/2020 07:53

4th February 2020

Stephen Robinson

Retweeted

Rob Clarke

@RobClarkeLab

·

4 Feb

Today we added the fifth submission from my lab to BioRxiv. The summation of more than 5 years research that culminated in a successful clinical trial

@ismenasg

@DrRachelEyre

@DrDAlferez

@asimslab

funded by

@BreastCancerNow

@ManchesterBRC

@TheChristie

.......


Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer

ABSTRACT

PURPOSE Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Sulforaphane (SFN) has previously been shown to target CSCs but its mechanism of action is unclear. Here we investigate SFX-01, a stabilised formulation of SFN, for its effects on breast CSC activity in ER+ preclinical models and to study its mechanism.

EXPERIMENTAL DESIGN CSC activity was measured by mammosphere formation efficiency (MFE), aldehyde dehydrogenase (ALDH) activity, and tumor formation using patient samples and patient-derived xenograft (PDX) tumors treated with SFX-01 alone or in combination with tamoxifen or fulvestrant. Gene expression and SFN target proteins in treated samples were assessed.

RESULTS SFX-01 reduced MFE of both ER+ primary and metastatic patient samples. Both tamoxifen and fulvestrant increased MFE and ALDH activity of PDX tumors, which was reversed by combination with SFX-01. SFX-01 significantly reduced tumor initiating cell frequency in secondary transplants at limiting dilution and reduced the formation of spontaneous lung micrometastases by PDX tumors in mice. Mechanistically, we establish that both tamoxifen and fulvestrant induce STAT3 phosphorylation. SFX-01 suppressed phospho-STAT3 and SFN directly bound STAT3 in patient and PDX samples. Analysis of ALDH+ cells from endocrine-resistant patient samples revealed activation of STAT3 target genes MUC1 ;and OSMR, which were inhibited by SFX-01 in patient samples. Increased expression of these genes after 3 months’ endocrine treatment of ER+ patients (n=68) predicted poor prognosis.

CONCLUSIONS Our data establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01 for improving clinical outcomes in ER+ breast cancer.

[moneymunch] 24/5/2020 12:50

ps that was quite a call by the old CEO, and maybe a clue to the potential transformational move ahead. Gla ;-)

"Deciding to leave Evgen was a tough call, but one that I made in the best interests of the shareholders.

The share price has been suppressed for a while and does not reflect the true and substantial value in the business.

What is needed now is fresh vision and new energy to take it to the next stage.

The Company remains a great business and I will continue to support them as a long-term shareholder."

[moneymunch] 24/5/2020 12:45

Just this minute taken the old one down, easier said than done with posts well and truly deeply set....;-)

[toffeeman] 24/5/2020 11:08

I've never been on the fence - you done the fence yet?

[moneymunch] 24/5/2020 09:33

Sulforaphane: Its “Coming of Age” as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease

Published 14 Oct 2019

[moneymunch] 23/5/2020 21:23

That's what you call research Tee Off Man, now stop sitting on the FENCE in judgement and say something about EVG....Ho ho ho..Good LUCK!!!! ;-)

[moneymunch] 23/5/2020 20:52

Stephen Franklin

Taking time out at n/a 3w · Edited

Hi all - I have been inundated with calls and messages since yesterday's announcement, so I thought I would make a short post on my personal Linked-In account. Deciding to leave Evgen was a tough call, but one that I made in the best interests of the shareholders. The share price has been suppressed for a while and does not reflect the true and substantial value in the business. What is needed now is fresh vision and new energy to take it to the next stage. The Company remains a great business and I will continue to support them as a long-term shareholder. I intend to take a short break now to recharge and will resurface in due course. Thank you to all those that have sent kind messages at this time of change. I also cannot stress how great the Evgen Board and management team have been in the way that this transition has been dealt with - much respect, Steve

[moneymunch] 23/5/2020 16:22

Lol, maybe there's a universal remedy out there, although better to be an optimist than a pessimist, they live longer happier lives. Gl :-)

[toffeeman] 23/5/2020 12:22

I have diagnosed the following 6 problems with you MM

Confirmation bias
Information bias
Loss aversion/endowment effect
Oversimplification tendency
Neglect of probability
Anchoring bias

You need to get treatment as soon as possible

[moneymunch] 23/5/2020 11:26

Lol...12.40pm Tee off man...;-))).....Fence manana and beyond....Gl ;-)

ps AstraZeneca!!!??????

"This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with POTENTIAL PARTNERS."

[toffeeman] 23/5/2020 10:54

You golfed and done the fence?

[moneymunch] 23/5/2020 09:32

AstraZeneca must be very much aware of the attributes of SFX-01...Gla ;-)


6/2/20

University of Manchester collaboration discovery

Gene signature identified which may determine response to SFX-01 in ER+ breast cancer treatment

Evgen closer to predicting which patients are most likely to benefit from breast cancer drug

Steve Franklin, CEO of Evgen Pharma, said: "This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with potential partners. The University of Manchester have been tremendous collaborators and we would like to thank them for their continued commitment and enthusiasm.


...................

Manchester solution: the world’s number one endocrine treatment

Manchester researchers have developed new approaches to endocrine therapy that have revolutionised breast cancer treatment worldwide.

“Through extensive close collaborative clinical and laboratory work with colleagues at locally based AstraZeneca, Manchester researchers have successfully improved treatments over the years. Today, more women presenting with early breast cancer are cured, remission in advanced disease lasts longer and survival is prolonged."



.........................

Broccoli-based' drug could help treat breast cancer

29 January 2020


A new drug based on a compound found in cruciferous vegetables could improve the effectiveness of breast cancer hormone therapies, new research suggests.


Scientists at the University of Manchester found that the drug SFX-01 could reverse or potentially prevent resistance to hormone therapies by blocking a chain of reactions within cancer cells known as STAT3.

Up to 80% of breast cancer cases are known as oestrogen receptor (ER) positive breast cancer, since the disease’s growth is encouraged by the oestrogen hormone.

Hormone therapy can be very effective in reducing the risk of recurrence, though it’s thought around a third of patients with ER positive breast cancer see their disease return within 15 years, with some cases being attributable to patients developing resistance to treatment.

The team in Manchester assessed how SFX-01 worked by itself, as well as in combination with the hormone therapies tamoxifen and fulvestrant. The drug was tested both in patient samples and mice to see how it can be used to treat breast cancer. They found that SFX-01 reduced the ability of breast cancer stem cells to form tumours in mice, while also reducing the ability of breast cancer cells to form secondary tumours in the mice’s lungs.

The researchers also examined gene activity levels within the breast cancer stem cells from hormone therapy-resistant tumour samples from patients, discovering how cancer stem cells relied heavily on the STAT3 signalling pathway. STAT3 is able to become active when hormone therapy is used and ultimately lead to treatment resistance. However, the researchers discovered that SFX-01 was able to block the STAT3 signalling pathway and reverse the effects that may lead to hormone therapy resistance.

The drug - developed by UK company Evgen Pharma - has previously shown promise in a phase II trial as a treatment for secondary breast cancer that is already resistant to hormone therapy. That trial showed that SFX-01 was able to delay the progression of incurable secondary breast cancer in women who had already developed resistance to hormone therapy.

The drug was inspired by the natural compound sulforaphane, which is abundant in vegetables such as rocket, broccoli and kale.

The scientists in Manchester now hope that the drug could be added tamoxifen or aromatase inhibitors to increase those drugs’ effectiveness in patients with primary breast cancer. More so, the team hopes that SFX-01 could be used as a new option to treat secondary breast cancer.

The study results were presented at the UK Interdisciplinary Breast Cancer Symposium, hosted by the charity, Breast Cancer Now, in Birmingham.

Co-author of the study Dr Bruno Simões, research fellow at the University of Manchester, said: “Oestrogen receptor positive breast cancer is the most common breast cancer. These cancers frequently develop resistance to hormone therapies, which is a major clinical problem that we are working to address.

“We are excited by our findings that combining standard hormone therapies with SFX-01 could improve treatment of some breast cancer patients by reversing resistance driven by the STAT3 signalling pathway.

“With the success of the recent clinical trial in secondary breast cancer, we hope that further studies will now help to identify which patients may benefit the most from this drug so that it could soon reach the clinic.”

Dr Simon Vincent, director of Research at Breast Cancer Now, which helped to fund the study, said: “It’s really exciting that SFX-01 could in future help to improve the effectiveness of hormone therapies and prevent or treat the return of breast cancer. While hormone therapy is effective for most women, around a third still see their breast cancer return and we urgently need to find new ways to tackle and prevent drug resistance.

“This important discovery reveals exactly how SFX-01 can help overcome hormone therapy resistance and we hope it could now open the door to it being used from the outset of treatment, to prevent resistance from developing in the first place.”

[bumpa33] 22/5/2020 18:51

Mesquida - the rules for TR1’s aren’t really policed in my experience. Yes, we’re going to phase 2 Monday as well, my gf keeps abreast of all the decrees etc...!

[moneymunch] 22/5/2020 17:41

You lucky people, I had a great time with the chaps at my mates villa in Quesada last October, and we were all planning to go again this September, but not too sure if that's going to happen as well as Kos with the family and friends in August:-(

[mesquida] 22/5/2020 17:41

Maybe, Bumpa, but that really would not be in accordance with the rules.
Are you moving into Phase 2 on Monday, we are and, boy, am i looking forward to spending a day on the beach !

[moneymunch] 22/5/2020 17:38

Lol...the last one was a special addition, VE day, Victory in Europe 75th Anniversary....and with the lock down here and the weather we've been having, it's just been like one long fiesta ( for the lucky ones of course ) it was 28 degrees here yesterday, and this coming week looks like another scorchio in my neck of the woods...Gl :-)

[bumpa33] 22/5/2020 17:34

I’m guessing we’ll get the TR1’s after the news, rather than before.

[bumpa33] 22/5/2020 17:32

Mesquida - I live in Spain too - Andalucia, the UK has a long way to catch us up with fiestas...!

[mesquida] 22/5/2020 17:30

I live in Spain so i had no idea that Monday will be a Bank Holiday. But surely you just had one the other day ? Thought that the idea of leaving Europe was to regain your national identity, but it seems that you are fast developing a Spanish style obsession with Fiestas !!!

[moneymunch] 22/5/2020 17:24

Maybe Tuesday mesquida, Monday's a Bank holiday. ;-)

[mesquida] 22/5/2020 17:22

Bumpa, see my post 1842, will be gobsmacked if we dont get some sort of rns on Monday morning , even if it is just a holding in company.